The Trump administration has released the 2026 quality ratings for Medicare health and prescription drug plans, showing that several leading players in the market slipped under stricter evaluation standards.
The Centers for Medicare and Medicaid Services (CMS) published the new ratings on Oct. 9, assessing Medicare Advantage (MA) and Part D plans based on criteria such as customer satisfaction, access to care, cancer screenings, and management of chronic conditions.
